Nature Medicine
5, 643 - 650 (1999)
doi:10.1038/9488
Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein
vaccineAurelio Cafaro1, Antonella Caputo2, Claudio Fracasso1, Maria T. Maggiorella1, Delia Goletti1, Silvia Baroncelli1, Monica Pace1, Leonardo Sernicola1, Martin L. Koanga-Mogtomo1, Monica Betti2, Alessandra Borsetti1, Roberto Belli1, Lennart Åkerblom3, Franco Corrias1, Stefano Buttò1, Jonathan Heeney4, Paola Verani1, Fausto Titti1
& Barbara Ensoli11
Laboratory of Virology, Istituto Superiore di Sanità
, 00161 Rome, Italy; 2
Department of Experimental and Diagnostic Medicine,
University of Ferrara, 44100 Ferrara, Italy
; 3
Department of Virology, The National Veterinary Institute,
Biomedical Centre, S-751 83 Uppsala, Sweden
; 4
Department of Virology, Biomedical Primate Research
Centre, Rijswijk ZH 2288 GJ, The Netherlands
Correspondence should be addressed to Barbara Ensoli ensoli@virus1.net.iss.itVaccine strategies aimed at blocking virus entry have so far failed to
induce protection against heterologous viruses. Thus, the control of viral
infection and the block of disease onset may represent a more achievable goal
of human immunodeficiency virus (HIV) vaccine strategies. Here we show that
vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein
is safe, elicits a broad (humoral and cellular) specific immune response and
reduces infection with the highly pathogenic simian-human immunodeficiency
virus (SHIV)-89.6P to undetectable levels, preventing the CD4+
T-cell decrease. These results may provide new opportunities for the development
of a vaccine against AIDS.
|
